Stay updated on DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial
Sign up to get notified when there's something new on the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page.

Latest updates to the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check23 days agoNo Change Detected
- Check44 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about a Phase II clinical trial for a cancer vaccine and the addition of collaborators and a new revision number. The core content regarding the study's purpose and methodology has been largely deleted.SummaryDifference41%
- Check66 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page.